Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...

The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax’s Investigational New Drug ...

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...

Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...

Standing desks may increase the risk of swollen veins and blood clots, a study in the International Journal of Epidemiology ...

Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor ...